Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Rituximab maintenance leads to better MCL outcomes

Vidal L et al. HemaSphere. 2018 Aug;2(4):e136.

Publish date:: August 24, 2018

Key clinical point: Rituximab maintenance therapy improves outcomes in patients with MCL.

Major finding: Compared with observation or maintenance interferon-alfa, maintenance rituximab was associated with reduced risk of progression-free survival events (HR, 0.58) and increased risk of grade 3 or 4 neutropenia (RR, 2.02).

Study details: A meta-analysis of six randomized controlled trials including 858 patients with MCL who had a response to induction therapy.

Disclosures: Dr. Vidal disclosed that she is an employee of Syneos Health. The study received no funding.

Read the story.

Citation:

Vidal L et al. HemaSphere. 2018 Aug;2(4):e136.

This Week's Must Reads

Phase II Trial of DNA Vaccine Encoding PAP in Patients with PCa ,

Utilization of Surgery for Post-prostatectomy Incontinence,

Claims Analysis of Advanced PCa Treatment Costs and Resource Use,

Testosterone Therapy Doesn't Increase Prostate Cancer Risk,

Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced PCa,